Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Luis De La Cruz-Merino, Lorenza Di Guardo, Jean Jacques Grob, Alfredo Venosa, James Larkin, Grant A. McArthur, Antoni Ribas, Paolo A. Ascierto, Jeffrey T.R. Evans, Antonio Gomez-Escobar, Giulio Barteselli, Susan Eng, Jessie Hsu, Anne Uyei, Brigitte Dréno

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. Methods: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms. Results: Eighty-six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemurafenib-treated patients vs seven events in seven vemurafenib-treated patients). Most patients with serous retinopathy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobimetinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observation and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff date (19 Sept 2014). Conclusions: Cobimetinib treatment was associated with serous retinopathy in patients with BRAF V600-mutated melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of serous retinopathy while patients are taking cobimetinib. Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012.

Original languageEnglish
Article number146
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - Jun 24 2017

Fingerprint

Melanoma
GDC-0973
Mitogen-Activated Protein Kinase Kinases
Photophobia
Screening
Visual Acuity
PLX4032
Therapeutics
Observation
Databases

Keywords

  • Cobimetinib
  • MEK inhibition
  • Melanoma
  • Serous retinopathy
  • Visual disturbance

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. / De La Cruz-Merino, Luis; Di Guardo, Lorenza; Grob, Jean Jacques; Venosa, Alfredo; Larkin, James; McArthur, Grant A.; Ribas, Antoni; Ascierto, Paolo A.; Evans, Jeffrey T.R.; Gomez-Escobar, Antonio; Barteselli, Giulio; Eng, Susan; Hsu, Jessie; Uyei, Anne; Dréno, Brigitte.

In: Journal of Translational Medicine, Vol. 15, No. 1, 146, 24.06.2017.

Research output: Contribution to journalArticle

De La Cruz-Merino, L, Di Guardo, L, Grob, JJ, Venosa, A, Larkin, J, McArthur, GA, Ribas, A, Ascierto, PA, Evans, JTR, Gomez-Escobar, A, Barteselli, G, Eng, S, Hsu, J, Uyei, A & Dréno, B 2017, 'Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study', Journal of Translational Medicine, vol. 15, no. 1, 146. https://doi.org/10.1186/s12967-017-1246-0
De La Cruz-Merino, Luis ; Di Guardo, Lorenza ; Grob, Jean Jacques ; Venosa, Alfredo ; Larkin, James ; McArthur, Grant A. ; Ribas, Antoni ; Ascierto, Paolo A. ; Evans, Jeffrey T.R. ; Gomez-Escobar, Antonio ; Barteselli, Giulio ; Eng, Susan ; Hsu, Jessie ; Uyei, Anne ; Dréno, Brigitte. / Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.
@article{b8a04ef9ad8f4a7ba457fca700a6dde2,
title = "Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study",
abstract = "Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. Methods: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms. Results: Eighty-six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemurafenib-treated patients vs seven events in seven vemurafenib-treated patients). Most patients with serous retinopathy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobimetinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observation and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff date (19 Sept 2014). Conclusions: Cobimetinib treatment was associated with serous retinopathy in patients with BRAF V600-mutated melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of serous retinopathy while patients are taking cobimetinib. Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012.",
keywords = "Cobimetinib, MEK inhibition, Melanoma, Serous retinopathy, Visual disturbance",
author = "{De La Cruz-Merino}, Luis and {Di Guardo}, Lorenza and Grob, {Jean Jacques} and Alfredo Venosa and James Larkin and McArthur, {Grant A.} and Antoni Ribas and Ascierto, {Paolo A.} and Evans, {Jeffrey T.R.} and Antonio Gomez-Escobar and Giulio Barteselli and Susan Eng and Jessie Hsu and Anne Uyei and Brigitte Dr{\'e}no",
year = "2017",
month = "6",
day = "24",
doi = "10.1186/s12967-017-1246-0",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

AU - De La Cruz-Merino, Luis

AU - Di Guardo, Lorenza

AU - Grob, Jean Jacques

AU - Venosa, Alfredo

AU - Larkin, James

AU - McArthur, Grant A.

AU - Ribas, Antoni

AU - Ascierto, Paolo A.

AU - Evans, Jeffrey T.R.

AU - Gomez-Escobar, Antonio

AU - Barteselli, Giulio

AU - Eng, Susan

AU - Hsu, Jessie

AU - Uyei, Anne

AU - Dréno, Brigitte

PY - 2017/6/24

Y1 - 2017/6/24

N2 - Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. Methods: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms. Results: Eighty-six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemurafenib-treated patients vs seven events in seven vemurafenib-treated patients). Most patients with serous retinopathy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobimetinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observation and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff date (19 Sept 2014). Conclusions: Cobimetinib treatment was associated with serous retinopathy in patients with BRAF V600-mutated melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of serous retinopathy while patients are taking cobimetinib. Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012.

AB - Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. Methods: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms. Results: Eighty-six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemurafenib-treated patients vs seven events in seven vemurafenib-treated patients). Most patients with serous retinopathy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobimetinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observation and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff date (19 Sept 2014). Conclusions: Cobimetinib treatment was associated with serous retinopathy in patients with BRAF V600-mutated melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of serous retinopathy while patients are taking cobimetinib. Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012.

KW - Cobimetinib

KW - MEK inhibition

KW - Melanoma

KW - Serous retinopathy

KW - Visual disturbance

UR - http://www.scopus.com/inward/record.url?scp=85021258986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021258986&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1246-0

DO - 10.1186/s12967-017-1246-0

M3 - Article

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 146

ER -